Table 2.
Comparison between N16+ and N16- patients (clinical-pathological data; chi-squared from proportions, one-way anova for continuous data)
| N0 Group (45 cases) N (%) | N1 group (75 cases) N (%) | N16+ group (15 cases) N (%) | P | |
|---|---|---|---|---|
| Gender | ||||
| Male | 27 (60) | 48 (64) | 5 (33) | N0 versus N1: NS N0 versus N16+: NS N1 versus N16+: NS |
| Female | 18 (40) | 27 (36) | 10 (67) | |
| Neoadjuvant treatments | 6 (13) | 5 (5) | 4 (27) | N0 versus N1: NS N0 versus N16+: NS N1 versus N16+: < 0.05 |
| Type of resection | ||||
| Whipple | 9 (20) | 24 (32) | 4 (27) | N0 versus N1: NS N0 versus N16+: NS N1 versus N16+: NS |
| PPPD | 36 (80) | 51 (68) | 11 (73) | |
| Tumour histology | ||||
| PDAC | 26 (58) | 48 (64) | 12 (80) | N0 versus N1: NS N0 versus N16+: NS N1 versus N16+: NS |
| Ampullary adenocarcinoma | 13 (29) | 17 (23) | 1 (7) | |
| Distal bile duct carcinoma | 6 (13) | 10 (13) | 2 (13) | |
| T status | ||||
| T1 | 5 (11) | 0 (0) | 0 (0) | N0 versus N1: <0.01 N0 versus N16+: <0.05 N1 versus N16+: NS |
| T2 | 13 (29) | 5 (7) | 0 (0) | |
| T3 | 23 (51) | 61 (81) | 14 (93) | |
| T4 | 4 (9) | 9 (12) | 1 (7) | |
| R status | ||||
| R0 | 39 (87) | 34 (45) | 6 (40) | N0 versus N1: <0.01 N0 versus N16+: <0.01 N1 versus N16+: NS |
| R1 | 6 (13) | 41 (55) | 4 (60) | |
| Harvested lymph nodes (mean, CI 95%) | 22 (19–27) | 32 (29–36) | 36 (24–49) | N0 versus N1: <0.01 N0 versus N16+: <0.01 N1 versus N16+: NS |
| LNR (mean, CI 95%) | 0 | 13 (11–16) | 27 (18–36) | N1 versus N16+: <0.01 |
| Adjuvant treatments | 20 (44) | 52 (69) | 13 (87) | N0 versus N1: <0.01 N0 versus N16+: <0.01 N1 versus N16+: NS |
NS, not significant; PPPD, pylorus-preserving PD; PDAC, pancreatic ductal adenocarcinoma; LNR, lymph-node ratio; CI, confidence interval.